ESC 365 - SGLT2 inhibitors should be first-line treatment in HFrEF - discussion

ESC Professional Premium Access

SGLT2 inhibitors should be first-line treatment in HFrEF - discussion

Session: Great Debate: controversies in the contemporary management of HFrEF

Topic: Cardiovascular Pharmacotherapy

Event: ESC Congress 2023

Congress Presentation

5 more presentations in this session

SGLT2 inhibitors should be first-line treatment in HFrEF: pro

Speaker: Professor M. Packer (Dallas, US)

SGLT2 inhibitors should be first-line treatment in HFrEF: con

Speaker: Professor J. Cleland (Glasgow, GB)

There is a role for anticoagulation in patients with HFrEF in sinus rhythm: pro

Speaker: Associate Professor F. Marin (Murcia, ES)

There is a role for anticoagulation in patients with HFrEF in sinus rhythm: con

Speaker: Doctor C. Reddin (Galway, IE)

There is a role for anticoagulation in patients with HFrEF in sinus rhythm - discussion

Access the full session

Great Debate: controversies in the contemporary management of HFrEF

Speakers: Professor M. Packer, Professor J. Cleland, Associate Professor F. Marin, Doctor C. Reddin

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by